ITEM 2.02. -RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On January 11, 2021, ImmunoGen, Inc. (also referred to as "we", "our", "us" or "ImmunoGen") disclosed at the 39th Annual JP Morgan Healthcare Conference that while we have not finalized our full financial results for the year ended December 31, 2020, we expect to report that we had approximately $294 million of cash and cash equivalents as of December 31, 2020. This amount is preliminary, has not been audited and is subject to change pending completion of our audited financial statements for the year ended December 31, 2020. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of December 31, 2020. It is possible that we or our independent registered public accounting firm may identify items that require us to make adjustments to the preliminary estimated cash and cash equivalents balance set forth above and those changes could be material.

The information in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

ITEM 7.01. - REGULATION FD DISCLOSURE.

Our management will present an overview of our business at the 39th Annual JP Morgan Healthcare Conference, beginning on January 11, 2021. Attached as Exhibit 99.1 to this current report on Form 8-K is a copy of the slide presentation we will be using at the conference.

The information referenced in this Item 7.01 and contained in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This current report on Form 8-K will not be deemed an admission as to the materiality of any information furnished pursuant to this Item 7.01 that is being disclosed pursuant to Regulation FD.

Please refer to slide 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

ITEM 9.01. - FINANCIAL STATEMENTS AND EXHIBITS.





(d): Exhibits



Exhibit No.      Description

99.1               Presentation Materials for JP Morgan 39th Annual Healthcare
                 Conference

104              Cover Page Interactive Data File (embedded within the Inline XBRL
                 (eXtensible Business Reporting Language) document)

© Edgar Online, source Glimpses